In contrast, however, both the serum retention properties, therapeutic efficacy and dose response kinetics of IGF-TRAP-3.3 were altered, as the optimal anti-metastatic effect in the colon carcinoma model was observed at the 10-fold lower doses of 0.5–1 mg/kg. Here, TRAF2 is linked to colon carcinoma.